Podcasts about bcl

Drs. Ghia and Scarfò discuss how CAR T-cell therapy is emerging as a powerful option for high-risk CLL and Richter transformation, especially in patients who have failed BTK and BCL-2 inhibitors. They stress that achieving deep remissions, choosing the right patients, and referring early to specialized centers are critical to improving outcomes.

"Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about chronic lymphocytic leukemia (CLL) treatment considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), including 45 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to treatment of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 184: Oncologic Emergencies 101: Tumor Lysis Syndrome ONS Voice articles: Fixed-Duration Therapy for CLL May Lower Cardiovascular Risks and Costs Less Than Continuous Treatment Individuals With CLL Face Increased Risk for Skin Cancer Master Hypersensitivity Reactions With These Strategies for Prevention and Management Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) ONS symptom management resources:  Fatigue Prevention of Bleeding Prevention of Infection: General Blood Cancer United: Chronic Lymphocytic Leukemia Treatment CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma Treatments Patient education sheets Acalabrutinib Ibrutinib Pirtobrutinib To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Blood work is a really nice way to evaluate if there is progression of the disease. And we evaluate their blood counts, specifically that complete blood count with a differential. We anticipate an elevated white count, and we anticipate that the absolute lymphocyte count is going to be elevated. That's characteristic of the disease. But what evolves and happens is that those numbers can rapidly change and what we get concerned about is if that white count—and the percentage of the absolute lymphocyte count specifically—starts to increase and double quickly." TS 5:52 "There are some components that help clinicians decide if we expect these things, this cadence of change to happen more readily, or if we feel really comfortable that the biology of the variants contributing to the type of CLL that each patient may have, they may not have that progression as quickly or at all. And so that kind of helps us in that follow-up and cadence. Oftentimes, we're checking blood work every three or six months. Some patients are on an annual interval of visits depending on that active surveillance. I think the other piece is that we have a relatively low threshold when there is a change in symptoms to just recheck those blood tests. It's nice that we can have a pretty readily available blood test to be able to give us a lot of information for these patients." TS 9:45 "When we think about CLL therapy, the old tried and true [treatments] still work: so, rituximab and obinutuzumab. And then we kind of start to think about pathways and the way, the mechanisms of which these treatments are integrated. We think about different pathways of how we can induce cell death, but also what are the potential side effects? What are the potential interactions?" TS 19:35 "I think a lot of this is about really having a clear understanding of the patient's goals and really being able to understand and align. I think we have a lot more data to provide guidance for those patients that really are wanting to know: What is my chance of overall survival? If I do this, does this mean that I don't need to ever be on treatment again? If I do it this way, does it mean that I have to come into clinic every week, or does it mean that I have to come in every week but I'm done? I do one year of treatment, and I don't have to think about treatment for a really long time based on some of these components that we can take into consideration." TS 24:36 "When we think about the B-cell lymphoma 2 (BCL-2) inhibitors, with venetoclax, I think the biggest component we think about is tumor lysis syndrome. It's so effective that these cancer cells release all of those electrolytes, potassium, phosphorus; you can see a rise in the lactate dehydrogenase and uric acid because those cells are breaking down. And so subsequently, that leads us to the consideration of, is the patient's kidney function able to clear it? And so a lot of frequent lab monitoring, a lot of hydration, supportive care with medications like ursodiol or allopurinol to really improve the ability to clear that cellular waste product so that it doesn't cause an oncologic emergency." TS 34:11

A #Research paper recently #Published in Volume 18 of Aging, titled “Slowing intervertebral disc aging in mice through long-term systemic treatment with the senolytic BCL-2/BCL-xL proteolysis targeting chimera (PROTAC) 753b,” examines whether the senolytic PROTAC 753b can slow age-related intervertebral disc degeneration (IDD) in mice. Long-term systemic treatment with 753b reduced key features of disc degeneration in 22-month-old male mice, including matrix breakdown, loss of disc aggrecan, age-related structural changes, and inflammatory markers such as IL-6 and TNFα. These benefits, however, were not observed in female mice, highlighting potential sex-based differences in the role of cellular senescence in IDD and the response to senolytic therapies. DOI - https://doi.org/10.18632/aging.206394 Corresponding author - Nam Viet Vo - nvv1@pitt.edu Abstract video - https://www.youtube.com/watch?v=t0z4MULDr1A Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206394 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, intervertebral disc aging, cellular senescence, senolytic, anti-apoptosis, PROTAC-753b To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

BUFFALO, NY — August 3, 2026 — A new #research paper was #published in Volume 18 of Aging on July 17, 2026, titled “Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice.” The study was led by first author Zachery R. Robinson, and corresponding author and Aging editorial board member Irina M. Conboy, both from the Department of Bioengineering and QB3 Institute, University of California, Berkeley. The researchers developed a new combination therapy that selectively targets both cancer cells and senescent cells by exploiting metabolic vulnerabilities shared by these two cell types. In laboratory studies and aged mice, the treatment selectively eliminated senescent cells and reduced cancer cell viability while improving physical performance and extending lifespan without significant toxicity to healthy tissues. Cancer and aging are closely linked. As people age, senescent cells accumulate throughout the body. Although these cells no longer divide, they remain metabolically active and release inflammatory molecules known as the senescence-associated secretory phenotype (SASP), which contributes to chronic inflammation, tissue dysfunction, and tumor progression. Existing therapies such as the BCL-2/BCL-xL inhibitor navitoclax (ABT-263) can eliminate both cancer cells and senescent cells but require doses that frequently cause thrombocytopenia, a potentially serious reduction in platelet counts that has limited their clinical use. Full press release - https://www.aging-us.com/news-room/new-drug-combination-targets-cancer-and-senescent-cells-while-extending-lifespan-in-old-mice DOI - https://doi.org/10.18632/aging.206399 Corresponding author - Irina M. Conboy - irina@generationlab.co Abstract video - https://www.youtube.com/watch?v=7p5JMvy9Twg Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206399 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, senescence, cancer, metabolic shift, ATP To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Somehow, Star Wars returned…to the Hey I Like That Game Podcast! Tony, Jake, and expert player Aditya ready our blasters in STAR WARS™ Battlefront II (Classic, 2005)!We also talk about Balatro, Noita, Mario Tennis Fever, Disc Golf Masters, Everything is Crab, and Deep Rock Galactic: Survivor Check out Aditya's highlight channel and the BCL stream. @Yezzirski100 on Discord if you're interested in jumping into competitive Star Wars Battlefront 2Got a game suggestion or want to join our Minecraft server? Reach out to us via Email or Twitch! Email: heyilikethatgame@gmail.com⁠Twitch: ⁠⁠⁠twitch.tv/heyilikethatgame⁠⁠⁠⁠⁠Heyilikethatgame.rocks⁠ #propagatethepodIt's OK to not be OK⁠

BUFFALO, NY — July 27, 2026 — A new #research paper was #published in Volume 18 of Aging on July 13, 2026, titled “Slowing intervertebral disc aging in mice through long-term systemic treatment with the senolytic BCL-2/BCL-xL proteolysis targeting chimera (PROTAC) 753b.” The study was led by first author Peter G. Alexander from the Ferguson Laboratory for Spine Research, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, and corresponding author Nam Viet Vo from the same institution. Intervertebral disc degeneration is a leading cause of chronic low back pain and disability. As discs age, they lose important structural components, become less able to absorb mechanical stress, and accumulate senescent cells—dysfunctional cells that stop dividing but continue releasing inflammatory molecules that contribute to tissue degeneration. Senolytic therapies, which selectively eliminate these cells, have emerged as a promising strategy to slow age-related diseases. In this study, researchers evaluated PROTAC 753b, a next-generation senolytic designed to target the anti-apoptotic proteins BCL-2 and BCL-xL while reducing the platelet toxicity associated with earlier drugs in this class. The researchers treated 16-month-old male and female mice with PROTAC 753b for six months and evaluated their intervertebral discs at 22 months of age using histology, molecular analyses, and measurements of inflammatory markers. The treatment significantly improved several measures of intervertebral disc health in aged male mice, preserving the extracellular matrix protein aggrecan and reducing matrix metalloproteinase (MMP)-mediated aggrecan breakdown, a hallmark of disc degeneration. In contrast, female mice showed little overall improvement, revealing a sex-specific response to treatment. Full press release - https://www.aging-us.com/news-room/senolytic-protac-slows-age-related-intervertebral-disc-degeneration-in-male-mice DOI - https://doi.org/10.18632/aging.206394 Corresponding author - Nam Viet Vo - nvv1@pitt.edu Abstract video - https://www.youtube.com/watch?v=t0z4MULDr1A Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206394 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, intervertebral disc aging, cellular senescence, senolytic, anti-apoptosis, PROTAC-753b To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

Show Notes Discover the heartbeat of Montreal's Jewish community with the Federation CJA 360 Podcast - your front‑row seat to the impact, innovation, and inspiration shaping Jewish life today. Each episode spotlights dynamic leaders, transformative initiatives, and powerful stories that highlight how Federation CJA is strengthening our community and building a vibrant Jewish future. Engaging, uplifting, and full of purpose, this is the podcast that brings our mission to life.Guest Information Samantha Mintz VinebergBio: A proud third-generation Montrealer, Samantha's commitment to the Montreal Jewish community began as a student leader at McGill University, where she earned her BCL and LLB degrees. Her legal background—including practicing tax and estate planning—eventually transitioned into a life dedicated to community impact.Samantha's journey with Federation CJA has spanned decades, from her early days as Chair of FedNext. Having served as the Chair of Women's Philanthropy from 2020–2021 and as a member of the Planning and Allocations Committee, Samantha has been a member of the FCJA board of directors since 2022 and was named First Vice Chair in September 2025., Samantha has consistently focused on the "rolled-up sleeves" work of community building.As a Wexner Heritage Program alum, Samantha is deeply invested in fostering the next generation of leaders. For her, ensuring a strong Jewish future in Montreal is about more than tradition; it's about creating a vibrant, secure, and thriving home for the generations to come.Link:@samvinebergSima GoelBio:Author, inspirational speaker, freelance writer and chiropractor, Iranian-born Dr. Sima Goel has dedicated her life to promoting the importance and fragility of freedom. Her journey began at age thirteen when she spontaneously defended a Baha'i classmate against a schoolyard bully, triggering events that would eventually take her into danger and far from her beloved, homeland.Dr. Goel lived under two dictatorships; The Shah and The Ayatollah Khomeini, she knows what is at stake. In her memoir, Fleeing the Hijab: A Jewish Woman's Escape from Iran, she shares how life in her beloved home changed inexorably from a paradise to a hell.With the publication of her memoir, Dr. Goel fulfilled a promise she made to herself on a dark night of her desert crossing: to share her story with as many people as possible and to tell of the power of faith, hope and perseverance. For Dr. Goel, freedom is a vital presence that transforms life. It allows you the right to self-expression, from the music you listen to, to the way you dress, to the books and ideals you study.Once a penniless political refugee, now an established Montreal professional, Dr. Goel shares her belief that an authentic life requires freedom of choice, the most precious commodity of all. She tells her story with dignity, passion, clarity and wisdom as she takes the audience on a journey that speaks to the power of resilience and courage. A master storyteller with a peerless perspective on the events that shaped her world, Dr. Goel leaves her audiences enlightened and inspired, and grateful for the myriad privileges available in modern democratic societies.Emmanuel TrauBio: An attorney from Israel with a background in Law and Middle Eastern Studies, Emmanuel Trau also has a foundation in advanced traditional Jewish studies and serves as a Shaliach (Special Emissary) with Federation CJA. He leads high-impact advocacy and Jewish identity initiatives, delivering interactive workshops for students and diverse community cohorts to build lasting resilience and a deeper connection to Israel.Chapters01:06 - First Word With Yair14:05 - Sima Goel38:43 -  5 Fun Minutes in Jewish History44:03 - Montreal Mega Mission 202752:28 - NewsBrief58:15 - Unexpected AlliesHost: Glenn J. NashenAbout the Host: Glenn J. Nashen is an award-winning public safety innovator and communicator, and longtime Cote Saint‑Luc City Councillor having founded CSL Emergency Medical Services and CSL volunteer Citizens on Patrol. Glenn was Director of Public Affairs and Communications at the Jewish General Hospital and CIUSSS West Central Montreal for 20 years and now serves as Podcast Producer and Director of Media Relations and Crisis Communications at Federation CJA, continuing his commitment to strengthening, safeguarding, and informing the community.Links: Blog, Facebook, X, LinkedIn.Featuring: Yair SzlakYair Szlak is the President and Chief Executive Officer of Federation CJA, a role he has held since 2018 after more than 15 years in senior leadership positions within the organization. A graduate of Osgoode Hall Law School, Yair is known as a skilled fundraiser and community builder. He has dedicated his career to strengthening Jewish life in Montreal and fostering a vibrant, resilient future for the community.Link: LinkedInReporter: Jordan StooplerJordan Stoopler is a copywriter and podcast reporter within Federation CJA's Strategic Marketing & Communications department. A graduate with journalism degrees from both Concordia University and Hofstra University on Long Island, New York, Jordan contributes to campaigns, weekly newsletters and other organizational communications. By night, Jordan is a freelance sports reporter, covering the local professional sports scene for the Canadian Press. He also produces and co-hosts Menschin' with the Boys, a podcast that shines a light on Jews and Israelis from across the sports world. Link: Podcast, Articles, 360 Newsletter Reporter: Dan Laxer from The SuburbanBio: Dan Laxer is a reporter with 30 years' experience in broadcast media and print journalism. He covers parts of the west end and the City of Montreal for The Suburban Newspaper. Follow him on Instagram and Facebook.Link: laxer@thesuburban.com.Podcast Website: FederationCJA.org/podcastPlease rate and review on podcast appContact the show: podcast@federationcja.orgFollow us on social media:X (formerly Twitter)InstagramFacebookLinkedInYouTubeShare this episode with a friend! If you enjoyed it, tag us on social media and let us know your favorite takeaway.The Pulse of Montreal's Jewish Community.

High‑risk MDS and AML continue to challenge clinicians, with limited durable responses and few options for older or treatment‑refractory patients. In this sponsored episode of The Top Line, host Stephanie Butler is joined by Dr. Amer Zeidan, Professor of Internal Medicine at Yale School of Medicine, to unpack new ASCO 2026 data that are drawing attention across the myeloid malignancies field.The discussion focuses on mesutoclax, a novel oral BCL‑2 inhibitor evaluated in combination with azacitidine. Dr. Zeidan breaks down early findings showing a 100% objective response rate with CR rate of 40% per IWG 2006 criteria and 90% composite complete response with CR in 60% in treatment‑naïve high‑risk MDS, along with strong efficacy and encouraging safety signals in AML, with over 80% composite CR, and with potent activity in TP53 mutant, as well as zero death within 30 or 60 days and rapid cytopenia recovery.Listeners will hear how mesutoclax’s potency, selectivity, and pharmacokinetic profile may overcome key limitations of existing BCL‑2 inhibitors, and what these results could mean for future frontline treatment strategies.See omnystudio.com/listener for privacy information.

Discover the heartbeat of Montreal's Jewish community with the Federation CJA 360 Podcast - your front‑row seat to the impact, innovation, and inspiration shaping Jewish life today. Each episode spotlights dynamic leaders, transformative initiatives, and powerful stories that highlight how Federation CJA is strengthening our community and building a vibrant Jewish future. Engaging, uplifting, and full of purpose, this is the podcast that brings our mission to life. Show Notes Discover the heartbeat of Montreal's Jewish community with the Federation CJA 360 Podcast - your front‑row seat to the impact, innovation, and inspiration shaping Jewish life today. Each episode spotlights dynamic leaders, transformative initiatives, and powerful stories that highlight how Federation CJA is strengthening our community and building a vibrant Jewish future. Engaging, uplifting, and full of purpose, this is the podcast that brings our mission to life.Guest Information Samantha Mintz VinebergBio: A proud third-generation Montrealer, Samantha's commitment to the Montreal Jewish community began as a student leader at McGill University, where she earned her BCL and LLB degrees. Her legal background—including practicing tax and estate planning—eventually transitioned into a life dedicated to community impact.Samantha's journey with Federation CJA has spanned decades, from her early days as Chair of FedNext. Having served as the Chair of Women's Philanthropy from 2020–2021 and as a member of the Planning and Allocations Committee, Samantha has been a member of the FCJA board of directors since 2022 and was named First Vice Chair in September 2025., Samantha has consistently focused on the "rolled-up sleeves" work of community building.As a Wexner Heritage Program alum, Samantha is deeply invested in fostering the next generation of leaders. For her, ensuring a strong Jewish future in Montreal is about more than tradition; it's about creating a vibrant, secure, and thriving home for the generations to come.Link:@samvinebergConsul General Eliaz LufBio: Eliaz Luf was appointed Consul General of Israel and moved to Montreal in summer 2025. He began his diplomatic career in 1995, serving in Warsaw, Poland, and then Mexico City, holding a number of positions at the Ministry of Foreign Affairs' headquarters in Jerusalem, was then posted as Deputy Head of Mission at the Israeli Embassy in Ottawa and subsequently served as Director of Department of Arms Export Control at the Strategic Division of Ministry of Foreign Affairs. Luf served as Deputy-Director General for International Relations Division, at the Israeli Ministry of Innovation Science and Technology. Luf holds an M.A. in Political Science from the National Security College and the University of Haifa, M.B.A. in Business Administration and B.A. (with honours) in General History and Political Science from the University of Haifa. He is a certified Mediator by the Ministry of Justice and volunteers as a mediator in a Community Mediation Center in the city of Ramle.Host & Show InfoHost: Glenn J. NashenAbout the Host: Glenn J. Nashen is an award-winning public safety innovator and communicator, and longtime Cote Saint‑Luc City Councillor having founded CSL Emergency Medical Services and CSL volunteer Citizens on Patrol. Glenn was Director of Public Affairs and Communications at the Jewish General Hospital and CIUSSS West Central Montreal for 20 years and now serves as Podcast Producer and Director of Media Relations and Crisis Communications at Federation CJA, continuing his commitment to strengthening, safeguarding, and informing the community.Links: Blog, Facebook, X, LinkedIn.Featuring: Yair SzlakYair Szlak is the President and Chief Executive Officer of Federation CJA, a role he has held since 2018 after more than 15 years in senior leadership positions within the organization. A graduate of Osgoode Hall Law School, Yair is known as a skilled fundraiser and community builder. He has dedicated his career to strengthening Jewish life in Montreal and fostering a vibrant, resilient future for the community.Link: LinkedInReporter: Jordan StooplerJordan Stoopler is a copywriter and podcast reporter within Federation CJA's Strategic Marketing & Communications department. A graduate with journalism degrees from both Concordia University and Hofstra University on Long Island, New York, Jordan contributes to campaigns, weekly newsletters and other organizational communications. By night, Jordan is a freelance sports reporter, covering the local professional sports scene for the Canadian Press. He also produces and co-hosts Menschin' with the Boys, a podcast that shines a light on Jews and Israelis from across the sports world. Link: Podcast, Articles, 360 Newsletter Karen PayneBio: Karen Payne is a Strategic Advisor in Antisemitism Advocacy at Federation CJA. She began her career as a corporate lawyer, practicing for over a decade in both New York and Montreal. In addition to her professional accomplishments, Karen has long been active in community philanthropy, within Solomon Schechter Academy and as a dedicated member of Federation CJA's Women's Philanthropy.  Driven by a deep commitment to combating antisemitism and strengthening the Jewish community, Karen joined Federation CJA to lead efforts in advocacy, education and resilience-building. She works closely with CIJA and helps with the strategies in educating and supporting community, and initiatives addressing antisemitism. Karen collaborates with a wide range of stakeholders to raise awareness, develop strategic responses, and implement impactful programs. Her unwavering dedication continues to inspire and empower the community in the ongoing fight against Jew-hatred.Emmanuel TrauBio: An attorney from Israel with a background in Law and Middle Eastern Studies, Emmanuel Trau also has a foundation in advanced traditional Jewish studies and serves as a Shaliach (Special Emissary) with Federation CJA. He leads high-impact advocacy and Jewish identity initiatives, delivering interactive workshops for students and diverse community cohorts to build lasting resilience and a deeper connection to Israel.Reporter: Dan Laxer from The SuburbanBio: Dan Laxer is a reporter with 30 years' experience in broadcast media and print journalism. He covers parts of the west end and the City of Montreal for The Suburban Newspaper. Follow him on Instagram and Facebook.Link: laxer@thesuburban.com.Podcast Website: FederationCJA.org/podcastPlease rate and review on podcast appContact the show: podcast@federationcja.orgFollow us on social media:X (formerly Twitter)InstagramFacebookLinkedInYouTubeShare this episode with a friend! If you enjoyed it, tag us on social media and let us know your favorite takeaway.The Pulse of Montreal's Jewish Community.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

Πώς έχασε η ΑΕΚ το BCL και τι συμβαίνει αλήθεια με τη σειρά που σώζει τα φετινά playoffs της Ευρωλίγκας; Hosted on Acast. See acast.com/privacy for more information.

Los titulares de la industria del deporte, con Patricia López, de 2Playbook.En baloncesto, la NBA y FIBA perfilan una liga europea de dos niveles, con la BCL como acceso, buscando integrar a los clubes de la Euroliga. En fútbol, se estima que el Mundial de 2026 generará 41.000 millones de dólares y creará más de 824.000 empleos globales. El cantante Drake, accionista minoritario del Venezia FC, ha incorporado a Tim Leiweke y Francesca Bodie (como presidenta) al club, con el objetivo de inyectar 100 millones de euros tras el ascenso a Serie A. Finalmente, el retail deportivo invierte más de 10.300 millones de dólares anuales en patrocinio y marketing para posicionarse en el deporte y la cultura. ¿Quieres más podcast de la industria del deporte? Apunta: SPORTS, INSIDE by 2Playbook 2Playbook Breaking News ⁠PRO Media & Content⁠: https://open.spotify.com/show/4pXpJ3NwsyO6L7M0W3a1cQ?si=956ce22086854bf0⁠ ⁠PRO Fitness: https://open.spotify.com/show/5yDmPCCzjwuOd43wJ6P29T?si=78f0cdd11a6c48e5 ⁠PRO Deporte Inclusivo: https://open.spotify.com/show/46tEMEcA5qg1QhAW0DCyMx?si=e173f9087ebf49e6 ⁠PRO Women in Sport: https://open.spotify.com/show/2d40NKSP1eFhN9YkmTTzNA?si=1f53010f4e8d4d4fContacto, sugerencias y feedback: podcast@2playbook.com

La provincia de Málaga y la capital malagueña alcanzan su récord máximo de población, superando los 1,8 millones de habitantes y los 600 mil respectivamente. Los socorristas que prestan su servicio en las playas de Málaga capital irán a la huelga desde mañana y hasta el domingo 17 de mayo para exigir más personal. La Fiscalía malagueña ha considerado que concurre la eximente completa de legítima defensa en el juicio del exmarido de Lucía Garrido. Fin de ciclo para el Unicaja que dijo adiós a su competición fetiche, la Final Four de la BCL, al caer ante un AEK de Atenas claramente superior por 65 a 78. Y quedan poco más de tres meses y medio para una nueva edición del "pitote del verano', el Canela Party, para el que justo hasta este viernes están disponibles los últimos packs de ahorro en abonos. Una edición que se celebrará del 27 al 29 de agosto, nos atiende a esta hora uno de sus promotores, Antonio Mata.Escuchar audio

Παρέα με τον Θάνο Τσίμπο από τη Μπανταλόνα, λίγες ώρες μετά τη νίκη της ΑΕΚ επί της Μάλαγα και με τη σκέψη στον τελικό του BCL απέναντι στη Ρίτας. Hosted on Acast. See acast.com/privacy for more information.

Con Albert Díez. Esta semana: los destacados de 'Showtime'. Recibimos a Andrés Jiménez, 'Jimix', un histórico de nuestro baloncesto. El fallecimiento de 'Piculín' Ortiz. La Final a 4 de la BCL en Badalona. Los playoffs de la NBA

In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy continues to give way to targeted and time-limited therapies, clinicians face an increasingly complex array of choices, each influenced by disease biology, patient preferences, and emerging clinical trial data. Key Discussion PointsThe episode focuses on the evolving frontline management of CLL and how clinicians can individualize therapy in an era of expanding options. Highlights include: Patient Evaluation and Diagnosis Considerations: Beyond traditional risk factors such as TP53 mutation and IGHV status, importance is also being placed on patient preference, comorbidities, and treatment goals (eg, time-limited vs continuous therapy) to guide treatment decisions. Therapy Selection and Sequencing Strategy: Dr Kittai offers his view on sequencing decisions in the front line: given the lack of robust comparative data, current evidence supports prioritizing the most appropriate upfront regimen rather than relying on uncertain sequencing strategies across agents. Insights From the AMPLIFY Trial (NCT03836261): With the recent February 2026 FDA approval of acalabrutinib (Calquence) plus venetoclax (Venclexta) in the front line, the discussion highlights progression-free survival (PFS) benefits seen in the AMPLIFY trial and favorable safety of the doublet. The Growing Role of Minimal Residual Disease (MRD): The discussion briefly pivots to the use of MRD testing in the clinic today, including data from trials like GLOW (NCT03462719) and FLAIR (EudraCT: 2013-001944-76), and its potential to guide treatment duration. Emerging Therapeutic Strategies in the Pipeline: The conversation looks to the future of CLL care, including Bruton tyrosine kinase (BTK) degraders, next-generation BCL-2 inhibitors, and novel combinations currently under investigation. Managing Richter's Transformation: Dr Kittai covers evolving combination approaches for this aggressive cancer that aim to target both CLL and lymphoma biology, moving beyond chemoimmunotherapy.

The honeymoon phase for Mike Malone in Chapel Hill is officially over. While the national media is enamored with his "NBA-style" recruiting and international pedigree, a deep dive into the advanced metrics suggests a deeply concerning trend for North Carolina fans.In this video, we break down why Malone's first major moves—specifically the acquisition of Neoklis Avdalas—might be a "reputation over reality" trap. We look at the alarming efficiency floor from Avdalas's time at Virginia Tech, where a 12.8 PER and 38.6% FG percentage have critics wondering if the Tar Heels are paying premium NIL prices for sub-replacement level production.https://theresourcenexus.com/mike-malone-unc-nba-hype-vs-cbb-substance-statistical-nightmare/We also dive into:The European Trend: Why Avdalas's struggles in the HEBA A1 and BCL (including a staggering 6.3 PER season) prove this isn't just a "transition" issue.The Overrated List: Why names like Karter Knox and Jarin Stevenson might be more about "tools" than actual winning basketball.The PG Problem: The fallout from losing five-star commit Dylan Mingo and what it means for the backcourt in 2026.Malone's Vision vs. CBB Reality: Is the "NBA Lens" a losing proposition in the transfer portal era?If you care about efficiency, PER, and winning basketball over recruiting stars, this is the breakdown you need.Timestamps:0:00 - The Mike Malone Era Begins1:15 - Neoklis Avdalas: The Statistical Red Flag3:45 - The European Context (HEBA A1 & BCL Metrics)5:30 - Chasing Hype: Karter Knox & The "Overrated" Trend7:15 - The Dylan Mingo Fallout9:00 - Final Verdict: Is UNC in Trouble?#UNC #NorthCarolina #MikeMalone #TarHeels #CBB #CollegeBasketball #TransferPortal #NeoklisAvdalas #NCAAB #BasketballAnalytics #NIL #ACC #GoHeels #CollegeHoops

Roy在舊金山看Stephen Curry與Kevin Durant的這周，正好是BCL East開打的日子，也正好小人物之友Sean香港進修空檔跟Kong一起在修頓場館看南華體育會vs烏蘭巴托野馬的BCL首戰，就這麼剛好，那一定得來聊聊2026 BCL吧！領航猿與國王再次代表台灣籃球參戰BCL East，同在B組的對手就是Kong與Sean現場觀賽的南華與野馬，4/6這一場糾纏到最後才分勝負的精采比賽，分別反映出兩隊的什麼特點？南華在球賽中場還搞退休儀式？領航猿與國王從小組賽晉級六強賽的機會有多大？且聽Kong與Sean的戰況回報與解析。焦點回到台籃，PLG重返台中，周日上演勇士在第四節被領航猿大逆轉！發生了什麼事？勇士能夠在本周與領航猿的例行賽最後交手調整回來嗎？TPBL戰況依然膠著，特攻雖然在愚人節被戰神翻盤，但周末兩戰贏得精彩、也再次擠進前四名，內馬的好表現能帶來更多變陣想像嗎？有機會進一步挑戰攻城獅佔據的第三名嗎？而剩下賽程較多、把排名主動權握在手中的攻城獅，近期又有哪些值得注意的球員？最後，夢想家雖然連勝中斷，但高柏鎧回歸、還有時間磨合陣容，這次能否帶著更好的狀態進軍季後賽？Roy外出取材的霹靂鍵盤，時長變短但內容沒有打折，歡迎小人物聽眾收聽、一起追蹤台籃動態、也別忘記要調整自己的Fantasy Basketball陣容！成為

Recorded- March 26, 2026 Uploaded- March 27, 2026   Pioneer League review week! But first we give an update on the BCL and its future. Plus further expansion could be coming soon.

Karolis Tiškevičius, Tomas Purlys ir Lukas Malinauskas „Basketnews.lt podkaste“ apžvelgė pergalingas Eurolygos vakarą Kaune, „Ryto“ naujoką ir katastrofą Panevėžio moterų krepšinyje. Tinklalaidės partneriai: Rexona - Nr. 1 antiperspirantas pasaulyje. Naujoji „Cooling“ linija su „ThermoCool“ technologija vėsina odą ir saugo 72 valandas. Novaturas – didžiausias kelionių organizatorius Baltijos šalyse. Atraskite naują kryptį – Maroką (Agadyrą): saulė, paplūdimiai ir išskirtinė kultūra. https://www.novaturas.lt/ Aibė – didžiausias prekybos tinklas Lietuvoje, turintis daugiau nei 900 parduotuvių. Čia visada rasite išskirtinių importuotų prekių, vietinės produkcijos bei „Kasdien geros kainos“ pasiūlymų, kuriems nereikia laukti akcijų. https://aibe.lt/ Nealkoholinis alus „Gubernija“, daugiau informacijos – https://gubernija.lt/ Išbandyk BasketNews Prediction žaidimą jau dabar! Prisijunk, spėk rungtynių baigtį ir varžykis dėl prizų: https://prediction.basketnews.lt/ Temos: Baimė dėl „Žalgirio“ ir užgniaužtas snaiperis (0:00); Masiulio dilema rungtynėse (9:41); Retas atvejis Kaune (13:55) Daugiau sau leidęs Tubelis (19:58); Aiškus „Žalgirio“ taikinys (24:59); Blogu laiku raunamės ant Šaro (26:20); Nustebinęs faktas apie žalgiriečius (29:26); Kodėl taip su Sirvydžiu? (31:53); Kur Nazas? (34:46); „Žalgiris“ Stambule ir iššūkis Šarui (39:08); Ekstrasensas Tiškevičius, „Ryto“ naujokai ir BCL playoff'ai (45:20); Moterų krepšinio katastrofa Panevėžyje (54:20); Aštrus Wiley atsakas „Rytui“ (1:07:22); Cirkai „Žalgirio“ rūbinėje (1:11:04).

Norėdami matyti visą podkastą spauskite čia: https://contribee.com/krepsinisnet 00:00 – filmai 03:48 – „Žalgirio“ pergalė prieš „Real“ 18:55 – laukia „Bayern“ 21:55 – „Ryto“ varžovas ketvirtfinalyje 30:50 – įspūdingas I.Sargiūno pasirodymas 40:45 – dar vienas antausis „Neptūnui“ 47:40 – „Gargždų“ pergalė prieš „Juventus“ 55:08 – „Žalgiris“ be problemų prieš „Šiaulius“ Rėmėjų dalyje aptartos šios temos: 1:01:46 – kodėl krepšinyje nėra „Transfermarkt“ platformos 1:04:55 – idealus LKL formatas ir komandos 1:11:00 – tarptautinių turnyrų įvertinimas 1:14:51 – ar V.Spanoulis yra pervertintas 1:18:09 – ką reikštų „Žalgirio“ ar „Ryto“ triumfai savo turnyruose 1:20:38 – „tamsusis arkliukas“ Eurolygos finalo ketvertui 1:22:22 – kodėl nėra „Žalgirio“ komplektacijos naujienų 1:24:21 – gynybos sistemos 1:29:00 – ar P.Motiejūnas yra pervertintas 1:34:59 – M.Strazelis „Žalgiriui“ 1:36:22 – BCL taškai 1:38:42 – ar legendos mirtį 1:40:14 – krepšinio žurnalistai UTMA turnyre 1:43:02 – kodėl „Žalgiris“ neinvestuoja daugiau į futbolo klubą 1:47:15 – 18-metis nori būti asistentu 1:48:52 – geriausi krepšinio pranešėjai 1:52:50 – gražiausi rinktinės marškinėliai 1:54:37 – gerai pateiktas klausimas 1:57:37 – „Žalgiris“ sutriuškino „Real“ antraštė 1:59:57 – žaidėjų dušas ir marškinėlių pasikeitimas 2:01:18 – ar futbolininkai flopais pranoksta krepšininkus 2:02:25 – kaip išdalintume 5 mln. LKL klubams

Recorded- March 19, 2026 Uploaded- March 21, 2026   We're looking back on the AAPB in 2025 this week and preview the BCL roster for 2026. Oh and it's finally been announced.

„Basketnews.lt podkaste“ Karolis Tiškevičius, Lukas Malinauskas ir Tomas Purlys klegėjo apie istorinį „Ryto“ pasiekimą ir tariamą žalgiriečio Moses Wrighto sutartį su „Barcelona“. Kauniečiai ginklų čia dar nesudėjo. Tinklalaidės partneriai: Telia internetas. Kad ir kokio interneto ieškotum – viską rasi Telia. 5G nešiojamas namų internetas su dovana (planšete ar kamera): https://bit.ly/4bSk5mX. Arba šviesolaidis su nuolaida iki -40 %: https://bit.ly/4bDSTqX Nord VPN. Apsilankykite https://nordvpn.com/basketnews ir dvejų metų planui gaukite keturis papildomus mėnesius. Jei nepatiks - per 30 dienų galite atgauti pinigus. Atsirado papildomų išlaidų? Vartojimo paskola - vienam ar keliems poreikiams. Pildyk paraišką internetu ir sužinok kiek gali pasiskolinti: https://inbank.lt/paskola/paskola-vartojimo Nealkoholinis alus „Gubernija”, daugiau informacijos – https://gubernija.lt/ Bilietai į BN LIVE su Arnu Butkevičiumi: https://tickets.paysera.com/lt/event/basketnews-live-su-arnu-butkeviciumi Temos: Kur mana kampiuteria ir kauniečio padėka (0:00); Pagaliau: „Rytas“ ir vėl ten! (2:00); „Ryto“ jaunimėlio ramstis, Dirkas Masiulis ir pašėlęs Bruhnke (7:10); Rekordinis Masiulis: „Laimėsim ir be Hardingo“ (10:58); Lukošiaus žvaigždutė, Speedy ir Marčelos konkurencija (12:40); Pusseptinto žaidėjo, Spartos režimas ir prastas „Galatasaray“ (14:54); Vokietis Lukošius (20:02); „Basketnews“ ir fanų dėmesys „Rytui“ (23:55); Būsimi „Ryto“ naujokai ir pinigai už pergales BCL (27:15); Žibėnas saugus, bet darbas nebaigtas (30:44); Stambului šitos rungtynės nusispjaut (33:53); Būsimas „Ryto“ varžovas ir garsūs vardai (36:28); AEK seneliai: pamirštas Kuzminskas ir Luko pabaiga (45:38); Prasta lietuvių situacija Europoje: kas geriausi? (53:23); Mintys nukėlė į „Ryto“ šlovę (54:42); Dvi pergalės nuo finalo ketverto (57:40); Eurolyga: „Partizan“ dovana „Žalgiriui“ ir Šaro kaltė (58:30); Likęs „Žalgirio“ kelias (1:00:19); Tai ar „Barcelona“ nusipirko Wright'ą? (1:01:29); Eurolygos biudžetų sprogimas: „Žalgiris“ juda kietai (1:06:45); Kokiu būdu „Rytą“ apgavo Wiley? (1:10:40); „Žalgiris“-„Real“: ką nuojauta „kižda“ Purliui? (1:23:06); Malinauskas ir Tiškevičius paskui „Žalgirį“ į Stambulą (1:25:48); Kauno garbės pilietis Šaras (1:27:28).

SRD: Hapoel Jerusalem readies for Turk, Holon to finish BCL campaign, Leumit Hoops back in actionMake sure to subscribe to The Sports Rabbi Show on iTunes, Spotify or Google Podcasts.Also download our fabulous new App available for both Android and iPhone!Click here for the iPhone AppClick here for the Android App

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations.First, Nicole Lamanna, MD, an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at Irving Medical Center, discussed relevant advancements in the management of chronic lymphocytic leukemia (CLL). She described how the FDA approval of fixed-duration acalabrutinib (Calquence) plus venetoclax (Venclexta) may affirm a shift away from standard chemoimmunotherapy in the field. Her discussion also emphasized evaluating the adverse effects and benefit/risk profiles of drug classes such as BTK inhibitors and BCL-2 inhibitors during the treatment decision-making process.Next, Rajshekhar Chakraborty, MD, an assistant professor of medicine in the Division of Hematology/Oncology at Irving Medical Center, touched upon critical themes related to the use of bispecific antibodies for patients with multiple myeloma and other plasma cell disorders. Educating providers on the utility of bispecific antibodies in earlier treatment settings, he noted, is one of the important challenges that the field must address to expand usage of these therapies in community practices. He also highlighted findings from the phase 3 MajesTEC-3 trial (NCT05083169) and how they support the clinical utility of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory disease.Finally, Hua-Jay “Jeff” Cherng, MD, an assistant professor of medicine in the Lymphoma Program in the Division of Hematology and Oncology at Irving Medical Center, detailed translational work that may shape clinical practice in the lymphoma space. He spoke about research aiming to move markers like ctDNA and minimal residual disease from “the bench to the bedside” as part of clinical decision-making for patients with diffuse large B-cell lymphoma (DLBCL). Other future focuses, Cherng said, include leveraging molecular genotyping to improve outcomes for higher-risk subgroups or even replacing chemotherapy with less toxic targeted agents.References CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting. News release. AstraZeneca. February 20, 2026. Accessed March 11, 2026. https://tinyurl.com/38zbx96s Mateos MV, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6

SRD: Hapoel Holon comes up short against Galatasaray in BCL, Israel Women's Basketball Nat'l Team prepares for WCQMake sure to subscribe to The Sports Rabbi Show on iTunes, Spotify or Google Podcasts.Also download our fabulous new App available for both Android and iPhone!Click here for the iPhone AppClick here for the Android App

This is Season 3, Episode 16 of The Run TMC Podcast. Duffy and Dave recap the MCAL and BCL playoffs, relive Selection Sunday at the Lodge, and break down the North Coast Section brackets — including the Marin Catholic boy's spot in the Open Division. Guests Ethan Kassel (Bay Preps Insider) and Jeff Spaulding provide bracket analysis and previews across divisions, while the hosts share local highlights, sponsor notes, and details on a limited-time Run TMC apparel drop. Show Notes The Run TMC Season 3 store is live Click here to shop: https://encr.shop/runtmcseason3 Our friend and former guest Dave Albee is battling kidney disease and needs help. More about his battle here.  (G): Content is Mostly Global Interest Topics (M): Content is Mostly Inside Marin Topics Musical intro credit to Stroke 9//Logo credit to Katie Levine Content and opinions are those of Dave, Duffy and their guests and not of affiliated organizations or sponsors email us at: theruntmcpodcast@gmail.com follow us on Instagram @theruntmcpodcast check out our website at: theruntmcpodcast.com thank you to our sponsors: The Hub in San Anselmo Encore Custom Apparel online and in downtown San Rafael  Batiste Rhum  The Social Klub in Sausalito San Domenico Nike Summer Basketball Camps

Los desalojos en la provincia por las borrascas se han reducido ligeramente a 344 personas y hoy también se recuperan las clases en todos los centros educativos, aunque la junta alerta que las próximas lluvias traerán incidencias. El presidente del gobierno, Pedro Sánchez, no ha dado fecha de cuándo se recuperará el servicio de alta velocidad desde Andalucía. La Guardia Civil ha solicitado colaboración ciudadana para identificar a una mujer cuyos restos mortales aparecieron dentro de una maleta en Benahavís en 2023. En deportes el Unicaja se complica su clasificación para cuartos en la BCL al caer en Alemania 80 a 71 en un mal partido ante el Wurzburg. Y el teatro del Soho acoge esta tarde el estreno nacional del musical Goya, La melodía de una leyenda, que estará en cartel hasta el sábado, hablamos hoy con su director, Juan José Afonso. Escuchar audio

Recorded- January 29, 2026 Uploaded- January 31, 2026   The guys talk about REV Entertainments recent investments in Indy Ball and the BCL.

In today's episode, the discussion features Guillermo Garcia-Manero, MD, who reviewed the clinical rationale for targeting BCL-2 in higher-risk myelodysplastic syndrome (MDS) and outlined the phase 3 GLORA-4 trial (NCT06641414) evaluating lisaftoclax (APG-2575) plus azacitidine (Vidaza) in this population. Dr Garcia-Manero is the chair ad interim in the Department of Leukemia in the Division of Cancer Medicine, as well as leader of the MDS/AML Moon Shot Program, at The University of Texas MD Anderson Cancer Center in Houston.In the exclusive interview, Dr Garcia-Manero contextualized lisaftoclax as a next-generation BCL-2 inhibitor being advanced as a hypomethylating agent (HMA) partner strategy intended to improve on outcomes historically achieved with azacitidine alone in higher-risk MDS. He emphasized that GLORA-4 is designed as a registrational, randomized trial to rigorously assess whether adding BCL-2 inhibition to standard HMAs can meaningfully deepen responses and translate into clinically relevant benefit. He also characterized the regimen's tolerability profile in a population that often requires careful supportive care and dose management.

Nella prima puntata registrata nel 2026 di Backdoor Call con Marco De Benedetto abbiamo parlato delle due vittorie importanti di Olimpia e Virtus in Eurolega. Dell'incredibile qualità di Valencia, del mercato con Olympiacos e Fenerbahce a farla da padrone e, purtroppo anche della sciagura Trapani in BCL. Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/backdoor-podcast--4175169/support.

Featuring perspectives from Dr Matthew S Davids, Dr Bita Fakhri, Prof Constantine Tam and Dr Jennifer Woyach, including the following topics:  Introduction (0:00) Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids (1:42) Case: A man in his mid 70s with a plethora of comorbidities but good performance status requires treatment for CLL — Bhavana (Tina) Bhatnagar, DO (14:58) Case: A man in his early 50s, a Jehovah's Witness, under observation for IGHV-mutated CLL develops pulmonary emboli and worsening lymphadenopathy, undergoes anticoagulation and begins therapy with zanubrutinib — Jennifer Yannucci, MD Case: A man in his mid 70s with a history of atrial fibrillation on apixaban receives zanubrutinib — Zanetta S Lamar, MD (22:30) Optimal Management of Adverse Events with Bruton Tyrosine Kinase and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Prof Tam (32:50) Case: A man in his mid 90s with CLL has concurrent locally advanced Merkel cell carcinoma of the scalp — Erik Rupard, MD (50:51) Case: A woman in her early 50s under observation for IGHV-unmutated CLL develops progressive splenomegaly and receives obinutuzumab/venetoclax — Sean Warsch, MD (54:28) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Woyach (1:05:51) Case: A man in his mid 70s with high-risk (del[TP53]) CLL experiences disease progression on ibrutinib and then venetoclax/obinutuzumab — Dr Bhatnagar (1:27:23) Case: A man in his early 80s with IGHV-unmutated CLL who previously received FCR now experiences disease relapse after 5 years of acalabrutinib, and a BTK C481S resistance mutation is detected — Priya Rudolph, MD, PhD (1:29:34) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Fakhri (1:34:08) Case: A man in his early 70s with multiregimen-relapsed CLL experiences an 18-month response to pirtobrutinib — Brian P Mulherin, MD (1:50:46) CME information and select publications

I'm so excited to have Dr. Bruce Lessey of ReceptivaDX join me on the podcast. Dr. Lessey has dedicated his research life to studying the lining of the uterus and more specifically, how to help embryos stick better. His research led to the discovery of the role of BCL-6 in the lining of the uterus as a diagnostic test patients can have done by their doctors to guide them toward the best protocol for transfer success. The test isn't for women just going through IVF either. This test can also be done to help women get an endometriosis diagnosis without going through a laparoscopy surgery. ⁠ ⠀ ⠀⁠ In addition to being a Fertility Doctor at The Fertility Center of the Carolinas, in Greenville SC, Dr. Lessey is also the scientific advisor for Cicero DX. His work on identifying BLC6 became the key component of the Receptivadx test. ⁠ ⠀ ⠀⁠ I'm delighted to have him on the show! Many IVF patients have benefited greatly from the Receptivadx test, and I'm looking forward to asking him a lot of questions about his work. ⁠ Read the full show notes and transcript on Dr. Aimee's website Find out more about ReceptivaDX here: https://receptivadx.com/ Would you like to learn more about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 15th, 2025 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Lukas Malinauskas, Karolis Tiškevičius ir Jonas Miklovas reaguoja į tragišką savaitę Lietuvos klubams. Dėmesio centre – „Žalgirio” pralaimėjimai, rungtynių dalyvių pasisakymai ir silpnas žurnalistų pasirodymas. Pokalbis pasisuko ir į NBA projektą Europoje, Tomą Balčėtį „Žalgiryje” bei skandalus Didžiojoje Britanijoje. Tinklalaidės partneriai: Saily - nauja eSIM paslauga rinkoje. Gaukite išskirtinę 15% nuolaidą „Saily“ duomenų planams! Naudokite kodą BASKETNEWS atsiskaitydami. Atsisiųskite „Saily“ programėlę arba apsilankykite https://saily.com/basketnews Naują LKL sezoną žiūrėkite per Telia Play. Krepšinis, filmai, serialai – viskas vienoje vietoje, visur, kur tik norit. Daugiau: https://www.telia.lt/privatiems/televizija/planai Sportuok didžiausiame sporto klubų tinkle Gym+! Rinkis iš 10 miestų ir net 34 lokacijų, įsigyk narystę jau šiandien: https://gymplius.lt/kainos/ Nealkoholinis alus „Gubernija”, daugiau informacijos – https://gubernija.lt/ Bilietai į pokalbių šou „Iš 9 metrų“ su Dariumi Songaila: http://bit.ly/46DLhU2 Temos: Podkasto sklaida, „Krepšinio pasaulyje” likimas ir Karolio herojus (0:00); Susmukęs „Žalgiriukas”, Butkevičiaus šou ir „pastatęs” žiūrovas (6:06); Ką reiškia „per gerai apie save pagalvojom”? (10:25); Italų gynybos erkės ir „Žalgirio” gynybos klaidos (15:11); Butkevičiaus gyvenimo rungtynės, įdirbio trūkumas ir Iggy vargai (26:33); Labai prasta prof. Messinos konferencija (34:23); Kas išeina ankščiau laiko – tas gaidys (43:51); NBA Europos planai – kas vyksta iš tikrųjų? (45:41); Tragiška savaitė ir kam pralaimėjo „Rytas”? (1:02:07); Kiek kainuoja arenos ir „sportinis principas” BCL (1:09:59); Kas po velnių vyksta su Didžiąja Britanija? (1:12:26); Ką „Žalgiryje” veiks Tomas Balčėtis, o Pocius „Reale”? (1:17:55); Roberto Javtoko bauda ir Balčiūno algoritmai/mechanizmai (1:24:30); Šiaulių mero byla, pokalbis su Songaila ir keiksmažodžių draudimas (1:30:01); Liako ir Audriaus rubrika: „Atspėk klubą” (1:35:40).

In today's episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibitors in the management of CLL. He highlighted the importance of molecular profiling for treatment rechallenge decisions and the potential for resistance mutations in this disease. He also noted the role of pirtobrutinib (Jaypirca) in overcoming treatment resistance, along with clinical signs indicating that patients may need a therapy change. Dr Dean also mentioned the high response rates seen with CAR T-cell therapy in patients with CLL and explained the possibility for combination regimens in CLL. Additionally, he expressed optimism about BTK degraders and bispecific antibodies.

Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. In this listener Q&A episode, the docs take on an emotionally tough but important topic: what to do after a failed IVF cycle. They dive deep into strategies to improve egg numbers, enhance embryo quality, and increase the chances of implantation success in future cycles. The conversation includes how a hysteroscopy can help detect fibroids or polyps that might create inflammation in the uterus, the impact of bacterial inflammation, and diagnostic tools like the ReceptivaDx test, which checks for the inflammatory marker BCL-6. BCL-6 may be linked with inflammation from endometriosis. The docs also touch on evaluating sperm DNA fragmentation and exploring the uterine microbiome. For those with positive signs of inflammation, treatment options such as Lupron or even laparoscopy to remove endometriosis are discussed. And don't miss the discussion on progesterone timing for frozen embryo transfer cycles—why the number of hours of exposure to progesterone can be critical for opening the window of implantation at just the right time. Tune in for a practical, science-based guide to navigating next steps after IVF doesn't go as planned. This episode was sponsored by ReceptivaDx.

Ibon Navarro:Ibon Navarro is a highly accomplished Head Coach in Europe and today he came to our summit in Vilnius to talk about the culture he created in Malaga, Spain! The two time King's Cup & back to back BCL championship coach has a lot of experience already and today we spoke about his practice habits as well as the habits he expects from his players. How the team culture is supposed to impact and help new players adapt easier and much more.Today's Topics:0:00 Intro2:10 Sleep & Off Season5:00 BCL Back to back process12:00 Alex Ferguson Quote14:20 James Clear Quote / Habits19:30 Information gathering / Recruitment22:50 Impact of culture25:15 Unconventional Practices32:00 Lessons from the past35:30 Substitution pattern42:00 Q&AFind Ibon Navarro here: IG: https://www.instagram.com/ibon.navarro76/ FB: https://www.facebook.com/ibontxun B8 Summit Website:www.b8summit.comThe Benas Podcast:www.bmatke.com #b8summit #basketballsummit #Vilnius #Lithuania #Basketball #podcast #conference #Growth #learning #conversations #Unicaja #Malaga #BCL #Champion 

John N. Allan, MD and Andrew H. Lipsky, MD discuss the evolution of CLL therapy and the power of doublet and triplet regimens, exploring combinations including BTK inhibitors with BCL-2 inhibitors and anti-CD20 monoclonal antibodies.

國泰世華 CUBE Podcast 節目「解鎖從容理財」由主持人小詹與證券投資分析師薯哥分享財經情勢與理財小故事的與你一起創造「從容投資、品味理財」的態度生活。立即收聽 ➡️ https://fstry.pse.is/7l4x2c —— 以上為 KKBOX 與 Firstory Podcast 廣告 —— 錄音當下PLG總冠軍賽第六戰落幕，領航猿在背水一戰中成功扳回一城，將系列賽逼進PLG史上首場Game 7！然而，當我們的目光還停留在PLG的激烈對決時，另一邊TPBL的季後賽舞台已悄然搭建完成。這場全新賽事的王者之爭，新聯盟的首個總冠軍究竟會花落誰家？ 本週，小人物上籃誠邀全家海神助教Sean，為大家帶來最專業的TPBL季後挑戰賽解析！Sean將為我們深度剖析戰神與雲豹的攻防特色，兩隊的優勢與短板又會如何影響比賽走向？這次的節目，絕對是所有台籃迷不容錯過的戰術盛宴！ 除了賽事分析，我們還準備了一些「殘酷數據」。一位熱心的小人物提供了今年各隊進場人數的詳細數據，與去年相比，數據的變化讓人驚訝：誰的進場人數暴跌？又是誰逆勢上漲？哪支球隊的公關票派得最凶？誰的票房數據最真實？這些問題，我們將用放大鏡逐一檢視，帶你看清台籃市場的真實面貌。 另外，最近有粉絲留言抱怨我們沒有針對PLG總決賽每場比賽進行分析。在這裡，我們要鄭重澄清：我們有做啦！只要加入我們的小人物上籃會員，就能聽到Roy又哭又笑的情緒起伏、小枚一針見血的評論，以及Kong專業同時一直挖苦Roy的賽事分析。想要掌握台籃季後賽的每場戰況，現在就訂閱小人物上籃會員吧！ 台籃的季後賽熱潮才剛剛開始，無論是PLG的Game 7還是TPBL的挑戰賽，每一場比賽都值得我們全情投入。快到各大podcast平台搜尋小人物上籃，持續鎖定霹靂鍵盤！ 成為

Featuring perspectives from Dr Jennifer R Brown and Prof Paolo Ghia, including the following topics: Introduction: The Chronic Lymphocytic Leukemia (CLL) Experience — 2000 to 2025 (0:00) Current Therapy Options with Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (9:42) Role of Venetoclax in the Treatment of CLL (26:52) AMPLIFY Trial and Other Novel BTK Inhibitor and Bcl-2 Inhibitor Combination Strategies (32:29) Noncovalent BTK Inhibitor Pirtobrutinib (46:47) CAR T-Cell Therapy; Novel Agents (56:12) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD CME information and select publications

In Part 2 of this candid global conversation, Karl Tabbakh returns to The Business of Doing Business to pull back the curtain on the economic uncertainty that's gripping both Canada and the U.S.—and what business leaders need to do about it.Dwayne and Karl dissect the real cost of tariffs, the psychological divide between the “haves” and “have nots,” and what a future recession could mean for Canadian competitiveness. They challenge leaders to rethink productivity, wealth distribution, and their own growth mindset in a time of instability.From political coalitions to personal responsibility, Karl doesn't hold back. If you're in business today, this episode is your compass in the chaos.Timestamps[00:01:00] – The danger of coalitions and the question of democratic representation[00:04:30] – Program creation vs. program funding: Canada's economic blind spot[00:08:30] – Do we have the GDP to fund the lifestyle we promise?[00:10:00] – Why Canada's mindset around growth is dangerously passive[00:13:30] – Who really pays the tariffs—and why they're hidden taxes[00:17:30] – Are tariffs a strategy or political theatre? Dissecting Trump's leverage[00:24:00] – The “Somewheres” vs. “Nowheres”: Stephen Harper's cultural divide explained[00:27:00] – The information echo chamber: Why we don't see disruption coming[00:29:00] – Education, taxation, and why we must fix the divide[00:36:00] – Capitalism's existential threat: What happens when the system loses balance[00:43:30] – CEO pay, productivity, and compensation in a modern economy[00:48:00] – Catching a falling knife: Should you invest in uncertain times?[00:52:00] – When clarity returns, capital will too: Preparing for the rebound[00:57:00] – The world is better than you think—but you have to choose that lens[00:59:00] – Final message: Educate yourself. Lead with purpose. Elevate others.About Karl TabbakhKarl Tabbakh is a lawyer, a business leader and a strategic advisor with over 20 years of international business experience. Karl's expertise is sought after to advise corporations, directors and business executives on a range of strategic issues and transactions both domestically and globally. He is a partner at McCarthy Tétrault LLP with a focus on M&A and private equity and serves on the firm's Senior Leadership Team as National Leader, Markets and International Business. He was appointed by the Government of Canada as Chairman of Invest in Canada, Canada's agency responsible for promoting, attracting and facilitating global foreign direct investments into Canada. He previously served as Chair of the Canadian Chamber of Commerce and was on the Board of directors of the Canada Arab Business Council. Karl is a regular speaker on matters of governance, global investment and mergers and acquisitions. In addition to his career in Canada, Karl spent eight years in the Middle East and four years in London, UK, where he developed a solid international network and gained an understanding of international business and investments. An active community leader, Karl supports and leverages his network to benefit many non-profit and local community service organizations, including as member of the Centraide/United Way campaign. Born in Syria, Karl immigrated with his parents to Canada at age 10. He holds an LLB from Osgoode Hall Law School in Toronto, a BCL from the Université de Montréal and a B.Comm from Université Laval in Québec City. Karl is fluent in French, English, and Arabic.Notable Quotes“Imposing a tariff isn't tax revenue....

In today's episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. In our exclusive interview, Dr Lamanna discussed how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in patients with CLL. She also highlighted important clinical features that guide the use of noncovalent BTK inhibitors—including sequencing strategies following covalent BTK and BCL-2 inhibitors, and emphasized the importance of balancing treatment efficacy with tolerability to optimize long-term disease management in CLL.

In one of the most urgent and eye-opening conversation, Dwayne sits down with Karl Tabbakh—top Canadian business strategist, international dealmaker, and former chair of the Canadian Chamber of Commerce—to unpack the global forces redefining the rules of business, politics, and leadership.Together, they explore what rising geopolitical tension, fractured trade alliances, and shifting world orders mean for entrepreneurs, CEOs, and decision-makers across North America. With experience advising on multi-billion-dollar cross-border transactions and leading strategic investments in Canada and the Middle East, Karl offers a rare lens into how to stay sharp—and sane—in chaotic times.This is part one of a two-part conversation filled with powerful insights on resilience, globalism, and the responsibilities of leadership in the modern era.Timestamps[00:02:45] – Why Karl was the first person Dwayne thought of for this global conversation[00:05:20] – Karl's career snapshot: from billion-dollar deals to chairing Invest in Canada[00:09:45] – A five-year vision framework for career growth and avoiding professional stagnation[00:13:00] – Why global exposure isn't just travel—it's transformational for decision-making[00:17:30] – The danger of only seeing the world through a North American lens[00:21:00] – Are we ignoring the signs of World War III? The breakdown of the post-WWII order[00:25:30] – What the markets are really saying about uncertainty and leadership[00:33:45] – Are nations acting out of fear, or a thirst for certainty?[00:40:00] – Why Canada must rethink its overreliance on one trade partner[00:52:00] – The hard truth about energy, natural gas, and global climate equity[01:03:00] – The upcoming Canadian election: What voters need to be asking[01:11:00] – Vision, will, and resources: Three pillars for Canada's next leader[01:15:00] – Final thoughts: Canada's opportunity to punch above its weight againAbout KarlKarl Tabbakh is a lawyer, a business leader and a strategic advisor with over 20 years of international business experience. Karl's expertise is sought after to advise corporations, directors and business executives on a range of strategic issues and transactions both domestically and globally. He is a partner at McCarthy Tétrault LLP with a focus on M&A and private equity and serves on the firm's Senior Leadership Team as National Leader, Markets and International Business. He was appointed by the Government of Canada as Chairman of Invest in Canada, Canada's agency responsible for promoting, attracting and facilitating global foreign direct investments into Canada. He previously served as Chair of the Canadian Chamber of Commerce and was on the Board of directors of the Canada Arab Business Council. Karl is a regular speaker on matters of governance, global investment and mergers and acquisitions. In addition to his career in Canada, Karl spent eight years in the Middle East and four years in London, UK, where he developed a solid international network and gained an understanding of international business and investments. An active community leader, Karl supports and leverages his network to benefit many non-profit and local community service organizations, including as member of the Centraide/United Way campaign. Born in Syria, Karl immigrated with his parents to Canada at age 10. He holds an LLB from Osgoode Hall Law School in Toronto, a BCL from the Université de Montréal and a B.Comm from Université Laval in Québec City. Karl is fluent in French, English, and Arabic.Notable Quotes“If World War III...

The offseason is nearly over so that means a visit from Kevin Tuve for some rock talk. Daryl Thompson's Blue Crabs tenure is over and so is the Cougars run in the BCL. We fill you up will all these and more on this week's show.

Recorded- April 7&11, 2025   Uploaded- April 12, 2025 Billy Horton joins the program to talk about last year in Yolo and the future in Marysville. Also a draft recap and a look at the past week in the BCL. And we finish the affiliated to independent review from last week along with a great promo from Grand Junction.

Featuring perspectives from Dr Nicole Lamanna and Dr Kerry Rogers, including the following topics: Introduction (0:00) Current Role of Covalent Bruton Tyrosine Kinase and Bcl-2 Inhibitors in Managing Chronic Lymphocytic Leukemia — Dr Lamanna (10:55) Novel Agents and Combination Strategies — Dr Rogers (31:21) CME information and select publications

TOYOTA限時優惠！即刻入主 RAV4, ALTIS,COROLLA SPORT,YARiS CROSS 免費升級JBL音響揚聲器，再享最高80萬零利率。打造車內頂級聽覺饗宴，買車就趁現在！ https://fstry.pse.is/7cy4sj —— 以上為 KKBOX 與 Firstory Podcast 廣告 —— 人家罷賽會被沒收比賽，但我們就算天打雷劈也是會繼續錄音。本週台籃有個令人振奮的消息，鋼鐵人終於拿下第二勝啦！擊敗的不是別人，正是聯盟龍頭aka台籃模範生桃園領航猿，到底他們施了什麼魔法，讓領航猿like a baby一樣，敗在他們手上？ 除了PLG，TPBL的卡位戰依舊激烈進行中，本以為雲豹前一週輸給戰神後要下去了，沒想到上週馬上討回來，屋漏偏逢連夜雨，戰神輸完雲豹還要再對上聯盟龍頭國王，毫無懸念吞下二連敗。目前戰神只領先雲豹1場，第三的海神更是和特攻只差0.5場，到底誰能搶到季後賽的最終席次，我們拭目以待。 聊完本週比賽，我們要跟大家隆重宣布，一年一度的台籃非官方獎項正式開跑啦，不管是哪個聯盟，哪支球隊，都都有參賽的資格，在開始投票前，我們預先討論了年度洋將和自創獎項：最佳副手獎，還沒想到投誰嗎？不妨收聽我們的節目，看看誰才是你心中最佳人選吧~ 成為